High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules
- PMID: 11406547
High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules
Abstract
Antitumor monoclonal antibodies must bind to tumor antigens with high affinity to achieve durable tumor retention. This has spurred efforts to generate high affinity antibodies for use in cancer therapy. However, it has been hypothesized that very high affinity interactions between antibodies and tumor antigens may impair efficient tumor penetration of the monoclonal antibodies and thus diminish effective in vivo targeting (K. Fujimori et al., J. Nucl. Med., 31: 1191-1198, 1990). Here we show that intrinsic affinity properties regulate the quantitative delivery of antitumor single-chain Fv (scFv) molecules to solid tumors and the penetration of scFv from the vasculature into tumor masses. In biodistribution studies examining a series of radioiodinated scFv mutants with affinities ranging from 10(-7)-10(-11) M, quantitative tumor retention did not significantly increase with enhancements in affinity beyond 10(-9) M. Similar distribution patterns were observed when the scFv were evaluated in the absence of renal clearance in anephric mice, indicating that the rapid renal clearance of the scFv was not responsible for these observations. IHC and IF evaluations of tumor sections after the i.v. administration of scFv affinity mutants revealed that the lowest affinity molecule exhibited diffuse tumor staining whereas the highest affinity scFv was primarily retained in the perivascular regions of the tumor. These results indicate that antibody-based molecules with extremely high affinity have impaired tumor penetration properties that must be considered in the design of antibody-based cancer therapies.
Similar articles
-
Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity.Cancer Res. 2000 Nov 15;60(22):6434-40. Cancer Res. 2000. PMID: 11103810
-
Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies.Cancer Res. 1998 Feb 1;58(3):485-90. Cancer Res. 1998. PMID: 9458094
-
Pharmacokinetics and biodistribution of genetically-engineered antibodies.Q J Nucl Med. 1998 Dec;42(4):225-41. Q J Nucl Med. 1998. PMID: 9973838 Review.
-
Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site.J Mol Biol. 1996 Nov 8;263(4):551-67. doi: 10.1006/jmbi.1996.0598. J Mol Biol. 1996. PMID: 8918938
-
Single-chain antibodies in pancreatic cancer.Ann N Y Acad Sci. 1999 Jun 30;880:263-80. doi: 10.1111/j.1749-6632.1999.tb09531.x. Ann N Y Acad Sci. 1999. PMID: 10415872 Review.
Cited by
-
Modern Technologies for Creating Synthetic Antibodies for Clinical application.Acta Naturae. 2009 Apr;1(1):32-50. Acta Naturae. 2009. PMID: 22649585 Free PMC article.
-
Therapeutic potential of a tumor-specific, MHC-unrestricted T-cell receptor expressed on effector cells of the innate and the adaptive immune system through bone marrow transduction and immune reconstitution.Blood. 2005 Jun 15;105(12):4583-9. doi: 10.1182/blood-2004-10-3848. Epub 2005 Mar 3. Blood. 2005. PMID: 15746083 Free PMC article.
-
Affibody-mediated tumour targeting of HER-2 expressing xenografts in mice.Eur J Nucl Med Mol Imaging. 2006 Jun;33(6):631-8. doi: 10.1007/s00259-005-0012-3. Epub 2006 Mar 15. Eur J Nucl Med Mol Imaging. 2006. PMID: 16538504
-
Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab.Blood. 2006 Oct 15;108(8):2648-54. doi: 10.1182/blood-2006-04-020057. Epub 2006 Jul 6. Blood. 2006. PMID: 16825493 Free PMC article.
-
Identification of internalizing human single-chain antibodies targeting brain tumor sphere cells.Mol Cancer Ther. 2010 Jul;9(7):2131-41. doi: 10.1158/1535-7163.MCT-09-1059. Epub 2010 Jun 29. Mol Cancer Ther. 2010. PMID: 20587664 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Medical
Miscellaneous